European CRO Federation

Tweet this page
<
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 25 Sep 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

100,000€ - 199,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

2 Fte (6)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    European CRO Federation   (EUCROF)

    EU Transparency Register

    898445414948-91 First registered on 26 Nov 2014

    Goals / Remit

    The objective of EUCROF (the European CRO Federation), a non-profit organisation founded in 2005, is to promote Clinical Research by improving the knowledge, competence/expertise and skills of Contract/Clinical Research Organisations (CROs) in Europe.
    The Federation represents and supports the interests of CROs in Europe towards regulatory bodies, pharmaceutical, biotech, medical device, patients associations and other healthcare-related entities, within the field of clinical research. As one of the stakeholders, EUCROF is interested in promoting and supporting high-quality clinical trials by observing internationally agreed ethical, technical and scientific principles. EUCROF organises and supports training and education programmes to increase the quality of clinical research and to improve collaboration and interaction amongst all stakeholders in the field in Europe. Active participation in international congresses and meetings further underlines the significant role of CRO (...)

    Main EU files targeted

    During the last year, EUCROF has performed many activities as stakeholder, invited to represent the Contract Research Organisations point of view on many Clinical Research issues, new rules and regulations during formal meetings with the European Medicinal Agency (EMA), Paediatric Research Consortia, Patient Associations and Conferences on Clinical Research:

    -EMA: EU clinical trials portal and Union database: meeting with stakeholders, Amsterdam
    -EMA: Participation to UAT for EU Portal
    - GCP Inspectors WG and interested parties Joint Meeting
    -Enpr-EMA meetings

    EUCROF has created 14 active working groups:
    1. Clinical Trials Centres
    2. Clinical Trials Legislation
    3. Clinical Trials Logistics
    4. Communication
    5. Early Phase
    6. Events and Training
    7. Innovative Medicines
    8. Medical Devices
    9. New Technologies
    10. Paediatrics
    11. Patients' Associations
    12. Pharmacovigilance
    13. Real World Data & Digital Health
    14. Clinical research Barometer

    EUCROF also has a Talent Engagement Task Force.

    EUCROF held its 7th European Conference on Clinical Research in Prague (Czech Republic) on 19 & 20 February 2024.

    Address

    Head Office
    EUCROF secretariaatp/a LB Finance
    Haarlem 2031 ET
    NETHERLANDS
    EU Office
    EUCROF secretariaatp/a LB Finance
    Haarlem 2031 ET
    NETHERLANDS

    Website

    http://www.eucrof.eu

  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    75%1
    25%5

    Lobbyists (Full time equivalent)

    2

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    The engaged members of the Executive Board:

    Dr Martine Dehlinger-Kremer (President)
    Dr Stefano Marini (Vice-President)
    Mr. Simon Lee (Secretary)
    Mr. Yoani Matsakis (Treasurer)
    Mr. Christophe Golenvaux (Board Member)

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Trade and business associations

  • Networking

    Affiliation

    The EUCROF is collaborating with further organizations:

    1. Association of Clinical Research Organizations or ACRO (in the USA)
    2. EFGCP, European Federation for Good Clinical Practice
    3. EPF


    Moreover, there is ongoing collaboration with representatives of the pharmaceutical industry, such as EFPIA.

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    100,000€ - 199,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    100,000€ - 199,999€

    Other financial info

    The costs are low compared to the number and time of people involved because their contribution is mostly on a voluntary basis, without compensation

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    By October 2014 EUCROF releases its Position Paper on “Transparency in Early Phase Clinical Research” published as official comment by EMA

    18 September 2015 EMA has published the Draft appendix on disclosure rules to the “Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014 - EUCROF submission of expert opinion on publication of Phase 1 summary results in relation to patent protection was essential contribution to the improvement of the document.
    Regarding the GDPR regulation, EUCROF is in a well-advanced process of EU GDPR authorities' approval on the first and up to-now unique Code Of Conduct related to Clinical Trial transparency conduct

    Other activities

    During the last year, EUCROF has performed many activities as stakeholder, invited to represent the Contract Research Organisations point of view on many Clinical Research issues, new rules and regulations during formal meetings with the European Medicinal Agency (EMA), Paediatric Research Consortia, Patient Associations and Conferences on Clinical Research

    EUCROF has created and manages 12 active working groups:
    1. Clinical Trials Centres
    2. Clinical Trials Legislation
    3. Communication
    4. Early Phase
    5. Events and Training
    6. Innovative Medicines
    7. Medical Devices
    8. New Technologies
    9. Paediatrics
    10. Patients' Association
    11. Pharmacovigilance
    12. Real World Data & Digital Health

    In this context, EUCROF is significantly progressing with its direct participation to the EMA GCP Inspectors Working Group (IWG), with the EUCROF WG on Clinical Trials in Paediatric Populations being invited to EMA meetings being part of working groups of Enpr-EMA and being an observer member of the Coordinating group of Enpr-EMA, with the WG on Clinical Trial Legislation analysing and suggesting changes to draft guidelines, concept papers or other legislation under public consultation.

  • Meetings

    Meetings

    None declared

Download this datacard